Liver Transplantation in Amyloidosis: When Is It Considered?

Liver transplantation in amyloidosis has a unique role because, in selected hereditary forms of amyloidosis, the liver is not simply an organ affected by disease. Instead, it is the major source of the circulating amyloidogenic precursor protein.

This is particularly important in hereditary transthyretin amyloidosis (ATTRv). Most circulating transthyretin is produced by the liver. Historically, replacing a liver that produces variant transthyretin with a donor liver producing wild-type transthyretin substantially reduced circulating variant TTR and became an important disease-modifying treatment for selected patients (1, 2).

However, the treatment landscape has changed. Modern TTR stabilizers and gene-silencing therapies can target the disease without major transplantation surgery. Consequently, liver transplantation is no longer considered first-line treatment for most patients with ATTRv and is now reserved for carefully selected circumstances (3, 4).

Liver transplantation should therefore be understood within the broader role of organ transplantation in amyloidosis, rather than as a routine treatment for every form of the disease.

Key principle: In hereditary ATTR amyloidosis, liver transplantation can reduce production of variant transthyretin because the liver produces most circulating TTR. However, transplantation does not remove existing amyloid deposits and does not guarantee that cardiac, neurologic, ocular or central nervous system disease will stop progressing.

Why the Liver Matters

The liver produces several proteins that can become amyloid precursors. Its importance differs substantially according to the type of amyloidosis.

In ATTR amyloidosis, hepatocytes produce most circulating transthyretin. In ATTRv amyloidosis, a pathogenic variant in the TTR gene results in production of structurally unstable transthyretin that can dissociate, misfold, and form amyloid fibrils.

By contrast, in AL amyloidosis, the amyloid precursor is an abnormal immunoglobulin light chain produced by a plasma cell or B-cell clone rather than by the liver. Similarly, in AA amyloidosis, the liver produces serum amyloid A in response to inflammation, but transplantation does not treat the underlying inflammatory process driving SAA production.

Therefore, the biological rationale for liver transplantation is strongest in selected hereditary amyloidoses in which replacing the liver directly changes production of the pathogenic precursor protein.

Why Transplantation Was Historically Used in ATTRv

The liver produces more than 95% of circulating transthyretin. This observation created the rationale for orthotopic liver transplantation in hereditary ATTR amyloidosis (1).

The first liver transplantation for hereditary ATTR amyloidosis was performed in Sweden in 1990 in a patient with the TTR Val30Met variant, now commonly described using current nomenclature as p.Val50Met. After transplantation, circulating variant TTR falls dramatically because the donor liver produces wild-type rather than variant transthyretin.

Early studies demonstrated that transplantation could slow or halt progression of neuropathy in appropriately selected patients and, in some cases, allow regression of visceral amyloid deposits (5).

Variant TTR-producing liver → donor liver producing wild-type TTR → major reduction in circulating variant TTR

This mechanism made liver transplantation the first major disease-modifying therapy for ATTRv amyloidosis. Nevertheless, subsequent long-term follow-up revealed that outcomes differed substantially according to genotype, age, phenotype, nutritional status, and pre-existing cardiac involvement.

Which Patients Historically Had the Best Outcomes?

Long-term experience from the Familial Amyloidotic Polyneuropathy World Transplant Registry showed that outcomes were not uniform across all patients.

Historically, the most favorable outcomes were observed in younger patients with early-onset p.Val50Met disease, relatively short disease duration, preserved nutritional status and limited cardiac involvement (2).

GeneReviews currently describes liver transplantation as a potential consideration in selected patients with p.Val50Met ATTRv, particularly when they are younger than 60 years, have relatively short disease duration, predominantly early neuropathic disease and no substantial cardiac or renal dysfunction (3).

However, these criteria should not be interpreted as universal transplant rules. Modern patient selection must also account for the availability and effectiveness of pharmacologic disease-modifying therapy, transplant-center expertise, and the patient’s individual genotype and phenotype.

Why Is Genetic Testing Essential?

ATTRv amyloidosis is genetically heterogeneous. Different TTR variants can produce substantially different patterns of neuropathy, cardiomyopathy, autonomic dysfunction, ocular disease, and other manifestations.

Therefore, genetic testing for ATTR amyloidosis is essential before considering liver transplantation. The result confirms hereditary disease and identifies the pathogenic variant, which can influence expected phenotype, prognosis, and suitability for transplantation.

Genetic counseling is also important because ATTRv follows an autosomal dominant inheritance pattern. Identifying the familial variant can allow appropriate testing and surveillance of adult relatives.

Importantly, liver transplantation has no disease-modifying rationale in wild-type ATTR amyloidosis (ATTRwt), because these patients do not have a pathogenic TTR variant produced by the native liver.

For readers comparing the two forms, see ATTR Wild-Type vs Hereditary ATTR Amyloidosis.

How Modern TTR Therapies Changed Treatment

The role of liver transplantation has changed dramatically with the development of TTR-directed pharmacologic therapies.

TTR stabilizers reduce dissociation of the transthyretin tetramer, while gene-silencing therapies reduce hepatic TTR synthesis. These approaches can modify ATTR disease without exposing patients to the operative risks of transplantation and lifelong post-transplant immunosuppression.

Current expert sources therefore no longer consider liver transplantation first-line therapy for most patients with ATTRv amyloidosis (3, 4).

Instead, transplantation may remain relevant for selected patients when:

The genotype and phenotype are historically associated with favorable transplant outcomes
Disease is relatively early
Significant cardiac disease is absent or limited
The patient has acceptable nutritional and functional status
Appropriate disease-modifying medication is unavailable, unsuitable, or ineffective
The expected long-term benefit of transplantation exceeds the risks
An experienced amyloidosis and liver-transplant center supports the strategy

Current perspective: Liver transplantation is now a highly selected treatment for ATTRv rather than the default disease-modifying therapy. Modern TTR stabilizers and gene-silencing treatments have substantially reduced its role.

Why Disease Can Progress After Transplantation

Liver transplantation markedly reduces variant TTR production, but it does not eliminate transthyretin from the circulation. The donor liver continues to produce normal, wild-type TTR.

Importantly, pre-existing amyloid deposits can act as a template for continued deposition of wild-type TTR. Research has demonstrated increasing proportions of wild-type TTR within cardiac amyloid deposits after liver transplantation (6, 7).

As a result, some patients continue to experience progression of cardiac or neurologic disease despite successful liver transplantation.

Cardiac Progression After Treatment

Cardiac progression is one of the most clinically important limitations of liver transplantation in ATTRv.

Patients with established cardiac amyloidosis before transplantation may continue accumulating wild-type TTR within existing myocardial amyloid deposits. This phenomenon has been documented pathologically after transplantation (6).

Therefore, cardiac assessment is central to transplant selection. Depending on the clinical situation, evaluation may include echocardiography, ECG, biomarkers, cardiac MRI and other investigations.

Where appropriate, clinicians may also use bone scintigraphy as part of the cardiac amyloidosis diagnostic pathway, while ensuring that AL amyloidosis has been appropriately excluded.

Neurologic and Other Disease Can Also Progress

Neuropathy may also continue to worsen in some transplanted patients. Long-term studies have documented ongoing deposition of wild-type TTR within amyloid fibrils after transplantation and clinical progression in a proportion of patients (8).

Furthermore, liver transplantation does not eliminate TTR production from extrahepatic sites such as the retina and choroid plexus. Therefore, ocular and leptomeningeal ATTR manifestations can still develop or progress after transplantation.

What Are the Long-Term Outcomes?

The Familial Amyloidotic Polyneuropathy World Transplant Registry provides the largest long-term experience with transplantation for hereditary ATTR amyloidosis.

An analysis of 1,940 transplanted patients reported an overall 20-year survival of approximately 55%. Outcomes were better in patients with early-onset p.Val50Met disease, shorter disease duration, and better modified body mass index at transplantation (2).

More recent long-term registry analysis covering more than three decades of experience confirmed substantial variation according to phenotype. Patients with predominantly neuropathic disease had better outcomes than those with cardiac or cardiorenal phenotypes. Median survival exceeded 20 years in several groups, but cardiac involvement remained an adverse prognostic factor (4).

These data highlight an important principle: the effectiveness of transplantation depends heavily on selecting the right patient at the right stage of disease.

Factor	Why it matters in liver-transplant evaluation
TTR genotype	Different variants produce different phenotypes and historical transplant outcomes. Early-onset p.Val50Met generally produced the most favorable results.
Age	Younger age has historically been associated with better long-term transplant outcomes.
Disease duration	Longer disease duration increases the likelihood of irreversible systemic amyloid damage before transplantation.
Cardiac involvement	Established cardiomyopathy can progress after isolated liver transplantation and strongly influences survival.
Neuropathy severity	Advanced neuropathy may not substantially reverse after transplantation and can limit functional recovery.
Autonomic dysfunction	Severe autonomic disease can affect blood pressure, nutrition, gastrointestinal function and post-transplant recovery.
Nutritional status	Low modified BMI and malnutrition have been associated with poorer outcomes.
Kidney function	Advanced irreversible kidney disease may influence eligibility or lead to consideration of combined-organ transplantation.
Availability of modern ATTR therapy	TTR stabilizers and silencers can provide disease-modifying treatment without transplantation and have changed the risk-benefit calculation.

When Is a Combined Heart–Liver Approach Considered?

Some patients with hereditary ATTR amyloidosis have both a significant variant-TTR-producing liver and advanced irreversible cardiac amyloidosis.

Historically, carefully selected patients in this situation underwent combined heart–liver transplantation. The liver transplant addressed production of variant TTR, while the heart transplantation replaced the severely amyloid-infiltrated heart.

Registry data include patients who underwent liver transplantation combined with heart and/or kidney transplantation, and selected centers have reported meaningful long-term survival (2, 9).

However, combined transplantation is complex and is not routinely appropriate for all ATTRv patients with cardiac involvement. Modern TTR-directed treatment has further changed the balance between isolated organ transplantation, combined-organ transplantation and pharmacologic therapy.

Combined heart–liver transplantation is a specialist-center decision. It may be considered in highly selected ATTRv patients with advanced irreversible cardiac disease when the expected long-term benefit justifies the risks of multiorgan transplantation.

What About Other Combined-Organ Strategies?

Severe irreversible renal disease may occasionally coexist with hereditary amyloidosis. In selected patients, transplantation strategies can therefore involve more than one organ.

However, the decision depends on whether kidney dysfunction is truly irreversible, the systemic amyloid phenotype and whether isolated liver transplantation would provide sufficient benefit.

For a detailed discussion of renal transplantation, see Kidney Transplantation in Amyloidosis.

Is Liver Transplantation Used for AL Amyloidosis?

Liver transplantation is not a standard disease-modifying treatment for AL amyloidosis.

In AL amyloidosis, amyloidogenic immunoglobulin light chains originate from an abnormal plasma-cell or B-cell clone. Replacing the liver therefore does not eliminate the source of the amyloid precursor.

Management instead focuses on controlling the hematologic clone. When amyloidosis is suspected, appropriate diagnostic evaluation may include monoclonal protein testing and, when required, tissue biopsy and amyloid typing.

Liver transplantation might theoretically arise in exceptional circumstances if a patient independently develops conventional end-stage liver disease or another transplant indication. However, this is very different from using liver transplantation to treat the underlying AL amyloidosis.

Is Liver Transplantation Used for AA Amyloidosis?

Similarly, liver transplantation is not a standard disease-modifying treatment for AA amyloidosis.

In AA amyloidosis, the liver produces serum amyloid A because chronic inflammation stimulates the acute-phase response. Replacing the liver does not remove the inflammatory disease that drives SAA production.

Therefore, treatment focuses on controlling the underlying inflammatory or infectious disorder and reducing persistent SAA production.

How Should Cardiac Disease Be Assessed?

Because cardiac amyloidosis strongly influences outcomes, careful cardiovascular evaluation is essential before considering liver transplantation for ATTRv.

The assessment may include:

Symptoms and functional status
Electrocardiography
Cardiac biomarkers
Echocardiography for cardiac amyloidosis
Cardiac MRI when clinically appropriate
Assessment for heart failure and arrhythmias
Evaluation of whether cardiac disease is likely to progress despite isolated liver transplantation

Patients with significant cardiac involvement should be assessed by an experienced multidisciplinary team that includes transplant hepatology, cardiology, advanced heart failure and amyloidosis specialists.

What Should Be Evaluated Before Liver Transplantation?

Evaluation should extend well beyond standard liver-transplant testing because ATTRv is a systemic disease.

Assessment	Why it matters
Confirm ATTRv diagnosis	Transplantation should only be considered after establishing the correct amyloid type and confirming a pathogenic TTR variant.
TTR genotype	The specific variant influences phenotype, prognosis and historical transplant outcomes.
Cardiac assessment	Significant cardiomyopathy may progress after isolated liver transplantation and may alter the transplant strategy.
Neurologic assessment	Establishes neuropathy severity, progression and functional consequences.
Autonomic function	Orthostatic hypotension and gastrointestinal autonomic dysfunction can affect operative and post-transplant risk.
Kidney function	Helps identify irreversible renal involvement and possible need for multiorgan transplantation.
Nutritional status	Malnutrition and low modified BMI have historically been associated with poorer transplant outcomes.
Ocular/CNS disease	Liver transplantation does not stop local TTR production within the eye or central nervous system.
Available TTR-directed therapy	Modern pharmacologic treatment may provide a safer or more appropriate disease-modifying option.
General transplant eligibility	Age, comorbidities, frailty, infection risk, malignancy risk, psychosocial support and operative risk must all be considered.

What Happens After Liver Transplantation?

Successful transplantation eliminates most production of variant TTR from the native liver, but lifelong follow-up remains necessary.

Post-transplant care includes standard monitoring of the liver graft, immunosuppression, infection risk, renal function and other transplant complications. At the same time, clinicians must continue monitoring ATTR disease.

Long-term follow-up may include:

Neurologic examination and functional assessment
Autonomic symptom assessment
Cardiac biomarkers and ECG
Serial echocardiography
Additional cardiac imaging when indicated
Renal function monitoring
Ophthalmologic surveillance
Assessment for leptomeningeal or central nervous system manifestations when clinically indicated
Nutritional assessment
Consideration of additional ATTR-directed pharmacologic therapy if disease progresses

Can Patients Need ATTR Medication After Liver Transplantation?

Yes. Some patients experience continued ATTR progression after successful liver transplantation.

This has created an emerging role for TTR-directed therapies after transplantation. Published reports and recent expert consensus have discussed stabilizers and gene-silencing therapy for selected post-transplant patients with progressive cardiac or neurologic disease (10, 11).

However, post-transplant ATTR treatment must be individualized because transplant recipients were excluded from many pivotal drug trials, and evidence remains more limited than in non-transplanted populations.

What Is Domino Liver Transplantation?

A liver removed from a patient with ATTRv may be structurally and functionally normal despite producing variant transthyretin. Historically, some of these explanted livers were transplanted into carefully selected recipients through a procedure called domino liver transplantation.

The rationale was that amyloidosis typically takes many years to develop, allowing the recipient to benefit from a functioning liver while expanding the donor pool.

However, recipients can eventually develop acquired ATTR amyloidosis because the transplanted liver continues producing variant TTR. Long-term studies have documented amyloid deposition and neuropathy in domino recipients (12, 13).

Therefore, domino transplantation requires careful recipient selection, informed consent and long-term surveillance.

Liver Transplantation and Amyloidosis in Africa

The role of liver transplantation in ATTRv across Africa must be considered within the realities of diagnostic and treatment access.

Hereditary ATTR can remain under-recognized where genetic testing, specialist neuropathy assessment, advanced cardiac imaging and TTR-directed therapies are limited. At the same time, liver transplantation itself is available in relatively few centers and requires substantial long-term infrastructure.

Therefore, priorities include:

Improving recognition of hereditary ATTR amyloidosis
Expanding access to TTR genetic testing
Strengthening multidisciplinary cardiac and neurologic assessment
Developing referral pathways to experienced amyloidosis centers
Improving access to modern ATTR-directed therapies
Building collaboration between amyloidosis specialists and transplant programs
Generating African data on ATTR genotypes, phenotypes and treatment outcomes

Patients with suspected or confirmed cardiac involvement also require appropriate evaluation within the context of cardiac amyloidosis in Africa.

Africa-focused priority: The first requirement is accurate diagnosis and genotype-defined ATTR care. Liver transplantation should only be considered after multidisciplinary assessment of the patient’s variant, phenotype, disease stage, cardiac involvement, available pharmacologic treatment and transplant feasibility.

Key Takeaways

Liver transplantation has a unique disease-modifying rationale in hereditary ATTR amyloidosis because the liver produces most circulating transthyretin.
Historically, transplantation produced particularly favorable outcomes in selected younger patients with early-onset p.Val50Met ATTRv and limited cardiac disease.
Liver transplantation is no longer first-line therapy for most patients with ATTRv. Modern TTR stabilizers and gene-silencing therapies have substantially changed treatment.
The donor liver continues producing wild-type TTR. Therefore, amyloid deposition—particularly within the heart—can continue after transplantation.
Genotype, age, disease duration, nutritional status, neuropathy and cardiac involvement strongly influence transplant suitability and prognosis.
Patients with advanced cardiac disease may occasionally undergo combined heart–liver transplantation at specialist centers.
Liver transplantation is not a standard disease-modifying treatment for AL or AA amyloidosis.
Long-term neurologic, cardiac, renal and ophthalmologic surveillance remains important after transplantation.
Some patients with disease progression after transplantation may require additional ATTR-directed pharmacologic therapy.
Accurate diagnosis, genetic testing and multidisciplinary assessment are essential before considering transplantation.

References

Medical Disclaimer

This article provides educational and informational content only and does not replace individualized medical advice, diagnosis or treatment. Liver transplantation for hereditary transthyretin amyloidosis is a highly specialized decision that requires multidisciplinary assessment of TTR genotype, disease phenotype, cardiac and neurologic involvement, disease stage, available pharmacologic treatment, general transplant eligibility and local transplant criteria.

LOG IN